Histidine is an essential amino acid behind histamine and the muscle compound carnosine. The case is believable but unproven: limited evidence suggests better blood-sugar handling and lower inflammation, mostly in people with low levels or metabolic strain. Around 4 grams daily appears low-cost and generally safe, with reduced zinc the main concern at higher intakes. (Full Review)

Protocol

Standard Dose

4–4.5 g/day

L-histidine; the dose range used in human benefit trials

Schedule

2–3 divided doses with meals

Improves tolerance and provides steadier substrate supply

Form

L-histidine or L-histidine HCl

Single-ingredient products; carnosine (1–2 g/day) is an alternative route

Time to effect

Metabolic & Inflammatory

~12 weeks

Horizon over which changes were measured in the principal trial

Single Dose

No acute effect

No meaningful immediate effects expected from one dose

Benefits

Medium: Improved insulin sensitivity and glycemic markers; reduced inflammation and oxidative stress

Low: Lipid profile improvement; protection in anemia of chronic kidney disease; improved skin barrier function; modest cognitive benefit

Speculative: Appetite regulation and body-weight reduction; sleep quality and stress response; longevity and healthspan

Contraindications

Histidinemia

Uncontrolled histamine intolerance or mast cell activation disorders

Severe renal impairment (advanced CKD not under specialist supervision)

Pregnancy and breastfeeding

Children (outside medical supervision)

Key Interactions

Zinc and copper (supplement interactions)

Iron supplements (supplement interaction)

Other antioxidant or anti-inflammatory supplements (carnosine, beta-alanine, taurine, alpha-lipoic acid, NAC)

Antihistamine and histamine-modulating drugs (diphenhydramine, MAO inhibitors, DAO-affecting drugs)

Proton-pump inhibitors and antacids

Risk & Side Effects

Low: Reduced serum zinc at high intakes; gastrointestinal discomfort

Speculative: Cognitive impairment at very high doses; elevated histamine-related symptoms; worsening of metabolic status in predisposed individuals

Monitoring

Marker	Target	Why
Fasting glucose	70–85 mg/dL	Tracks glycemic response
Fasting insulin / HOMA-IR	Insulin <6 µIU/mL; HOMA-IR <1.5	Primary metabolic outcome in trials
HbA1c	<5.4%	Average blood sugar over ~3 months
hs-CRP	<1.0 mg/L	Marker of systemic inflammation targeted by histidine
Serum zinc	90–110 µg/dL	Detects histidine-induced zinc depletion
Serum histidine	Within or above lab reference range	Confirms repletion in deficiency states
Lipid panel (total cholesterol, triglycerides)	TC <180 mg/dL; TG <100 mg/dL	Secondary metabolic outcome

Cadence: Baseline, then at ~12 weeks; every 3–6 months for long-term high-dose users, with attention to serum zinc

Qualitative Assessment

Appetite and satiety (any reduction in hunger or food intake)
Energy levels and daytime alertness
Sleep quality
Skin condition (particularly for those with barrier-related skin concerns)
General sense of well-being and absence of gastrointestinal discomfort

Histidine for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment